Evidence map›Paper›PMID 41278342›Full record

ArticleKidney international reports2025

Vincristine Treatment Protects Against Podocyte Damage in Focal Segmental Glomerulosclerosis.

William J Mason, Jennifer C Chandler, Alice M Gage, Gideon Pomeranz, Karen L Price, Marilina Antonelou, Scott R Henderson, Laura Perin, Stefano Da Sacco, Alan D Salama and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

William J MasonDevelopmental Biology and Cancer Research and Teaching Department, Great Ormond Street Institute of Child Health, Faculty of Population Health Sciences, University College London, London, UK.
Jennifer C ChandlerDevelopmental Biology and Cancer Research and Teaching Department, Great Ormond Street Institute of Child Health, Faculty of Population Health Sciences, University College London, London, UK.
Alice M GageUniversity College of London Centre for Kidney and Bladder Health, Division of Medicine, Faculty of Medical Sciences, University College London, London, UK.
Gideon PomeranzDevelopmental Biology and Cancer Research and Teaching Department, Great Ormond Street Institute of Child Health, Faculty of Population Health Sciences, University College London, London, UK.
Karen L PriceDevelopmental Biology and Cancer Research and Teaching Department, Great Ormond Street Institute of Child Health, Faculty of Population Health Sciences, University College London, London, UK.
Marilina AntonelouUniversity College of London Centre for Kidney and Bladder Health, Division of Medicine, Faculty of Medical Sciences, University College London, London, UK.
Scott R HendersonUniversity College of London Centre for Kidney and Bladder Health, Division of Medicine, Faculty of Medical Sciences, University College London, London, UK.
Laura PerinGOFARR Laboratory for Organ Regenerative Research and Cell Therapeutics in Urology, Division of Urology, The Saban Research Institute, Children's Hospital Los Angeles, Los Angeles, California, USA.
Stefano Da SaccoGOFARR Laboratory for Organ Regenerative Research and Cell Therapeutics in Urology, Division of Urology, The Saban Research Institute, Children's Hospital Los Angeles, Los Angeles, California, USA.
Alan D SalamaUniversity College of London Centre for Kidney and Bladder Health, Division of Medicine, Faculty of Medical Sciences, University College London, London, UK.
David A LongDevelopmental Biology and Cancer Research and Teaching Department, Great Ormond Street Institute of Child Health, Faculty of Population Health Sciences, University College London, London, UK.
Ruth J PepperUniversity College of London Centre for Kidney and Bladder Health, Division of Medicine, Faculty of Medical Sciences, University College London, London, UK.

Funding

Wellcome Trust 220895
6 · The paper itself

Abstract

Introduction: Focal segmental glomerulosclerosis (FSGS) is associated with podocyte damage resulting in cytoskeletal alterations leading to foot process effacement. Vincristine is a chemoprotective drug which alters cytoskeletal microtubules and has been used clinically to reverse FSGS. However, the mechanisms underlying the beneficial effect of vincristine are not understood. Methods: Immortalized human podocytes were exposed to serum obtained from an adult index patient with FSGS before, during, and after vincristine treatment. We examined the podocyte transcriptome by RNA-sequencing alongside cytoskeletal structure and filtration barrier integrity using a glomerulus-on-a-chip (GOAC) model. Results: Podocytes exposed to serum from the index patient with FSGS during or after vincristine treatment contained lower levels of genes associated with microtubule function compared with cells stimulated with serum collected during disease presentation. Presentation serum altered tubulin and F-actin patterning, changes prevented when podocytes were exposed to sera taken during or after vincristine treatment and when vincristine was added to presentation serum. IgG depletion experiments revealed that podocyte damage initiated by the index patient presentation serum was not due to circulating autoantibodies. Addition of serum from 3 more patients with FSGS also caused podocyte tubulin disorganization which was prevented by vincristine. Addition of FSGS serum to the GOAC led to increased albumin permeability in 2 patients, which could be prevented by vincristine. Conclusion: Vincristine protects against pathological changes induced by FSGS serum, with preservation of tubulin and F-actin organization in podocytes. Understanding whether vincristine exerts similar effects in other patients with FSGS warrants further investigation to advance our knowledge of this alternative therapeutic.

Indexed as

F-actinfocal segmental glomerulosclerosisglomerular diseasemicrotubulespodocytesvincristine

Identifiers

PMID41278342
PMCPMC12640030

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.